<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Pilewski, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ramsey R Hachem, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic lung allograft dysfunction (CLAD) remains a major cause of morbidity and mortality following lung transplantation [<a href="#rid1">1</a>]. Survival data from the registry of the International Society for Heart and Lung Transplantation (ISHLT) [<a href="#rid2">2</a>] demonstrate a significant improvement in the early (up to one year) survival of transplant recipients over the past two decades; however, the rate of decline in survival after the first year is unchanged (<a class="graphic graphic_figure graphicRef64657" href="/d/graphic/64657.html" rel="external">figure 1</a>). </p><p>The clinical syndrome of CLAD and the infectious complications related to its treatment with intensified immunosuppression are the major causes of late morbidity and mortality after transplantation [<a href="#rid2">2</a>].</p><p>In May 2019, the International Society for Heart and Lung Transplantation (ISHLT) published guidelines that defined CLAD as the umbrella term, encompassing multiple phenotypes, bronchiolitis obliterans syndrome (CLAD-BOS) and restrictive allograft syndrome (CLAD-RAS) [<a href="#rid1">1</a>]. It is important to note that pre-2010 studies (and likely some 2010 to 2019 studies) labeled the majority of patients with CLAD as BOS even if they had other phenotypes.</p><p>The clinical aspects and treatment of CLAD, with a focus on the BOS, are discussed here. The epidemiology, clinical presentation, evaluation, diagnosis, treatment, and prognosis of RAS are discussed elsewhere. Issues related to acute lung transplant rejection, antibody-mediated lung transplant rejection, general transplantation immunobiology, and other causes of bronchiolitis are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128271.html" rel="external">"Chronic lung allograft dysfunction: Restrictive allograft syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16926.html" rel="external">"Evaluation and treatment of antibody-mediated lung transplant rejection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7346.html" rel="external">"Transplantation immunobiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4323.html" rel="external">"Overview of bronchiolar disorders in adults"</a>.)</p><p></p><p class="headingAnchor" id="H5794767"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>CLAD is an umbrella term describing a significant decline in lung function after lung transplantation in the absence of other identifiable causes [<a href="#rid1">1</a>]. CLAD is defined as a substantial and persistent decline (≥20 percent) in forced expiratory volume in one second (FEV<sub>1</sub>) when compared with the posttransplant baseline, which is itself defined as the average of the two maximal posttransplant FEV<sub>1</sub> values that are at least three weeks apart [<a href="#rid3">3</a>]. If alternate diagnoses are identified at the time of CLAD onset (eg, acute rejection or infection, which represent important CLAD risk factors) but allograft dysfunction does not resolve after treatment, CLAD onset is defined at the first drop in FEV<sub>1</sub>. If the alternate condition is considered irreversible (eg, pneumonectomy, new airway stenosis), a new FEV<sub>1</sub> baseline can be set [<a href="#rid1">1</a>]. A classification scheme is in use that takes into account diagnostic uncertainty early in the CLAD course (<a class="graphic graphic_figure graphicRef130430" href="/d/graphic/130430.html" rel="external">figure 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possible CLAD</strong> – New allograft dysfunction with an FEV<sub>1</sub> decline by ≥20 percent of posttransplant baseline, lasting &lt;3 weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Probable CLAD</strong> – Identified by two FEV<sub>1</sub> values that are ≥20 percent below the posttransplant baseline and are at least three weeks, but ≤3 months, apart.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definite CLAD</strong> – Consistent lung allograft dysfunction with FEV<sub>1</sub> decline by ≥20 percent of posttransplant baseline lasting &gt;3 months, as documented by FEV<sub>1</sub> measurements.</p><p></p><p>CLAD severity is determined based on the change in FEV<sub>1</sub> from baseline [<a href="#rid1">1</a>]. (See <a class="local">'CLAD staging (severity)'</a> below.)</p><p class="headingAnchor" id="H1572993585"><span class="h1">CLAD PHENOTYPES</span><span class="headingEndMark"> — </span>The 2019 International Society for Heart and Lung Transplantation (ISHLT) guidelines define four phenotypes of CLAD (<a class="graphic graphic_table graphicRef141258" href="/d/graphic/141258.html" rel="external">table 1</a>), which should be identified at the time of CLAD onset, based on the observed physiologic and radiographic patterns [<a href="#rid1">1</a>]. Measurements of FEV<sub>1</sub>, forced vital capacity (FVC), total lung capacity (TLC), and a chest computed tomography (CT) are required for an adequate phenotype classification.</p><p class="headingAnchor" id="H3432916650"><span class="h2">Bronchiolitis obliterans syndrome</span><span class="headingEndMark"> — </span>BOS is the predominant phenotype of CLAD and presents clinically as obstructive lung disease detected as a decline in FEV<sub>1</sub> from the posttransplant baseline, associated with a FEV<sub>1</sub>/FVC &lt;70 percent, with no restriction and no persistent fibrotic-like opacities. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H2547790752"><span class="h2">Restrictive allograft syndrome (RAS)</span><span class="headingEndMark"> — </span>The RAS phenotype is defined as CLAD with a restrictive defect (TLC &lt;90 percent of the posttransplant baseline, defined as the average of the two TLC values measured at, or near, the same time as the two baseline FEV<sub>1</sub> measurements), persistent fibrotic-like opacities, and no obstruction. While the imaging assessment remains quite subjective, opacities consistent with RAS are currently defined as those that (1) look like parenchymal or pleural fibrosis, (2) are likely to cause restrictive physiology, and (3) are persistent.</p><p class="headingAnchor" id="H2129423713"><span class="h2">Other phenotypes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed</strong> <strong>CLAD</strong> – CLAD with the combination of obstruction and restriction, in the presence of persistent fibrotic-like opacities [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Undefined CLAD</strong> – A category characterized by either the presence of obstruction and persistent opacities without restriction or by obstruction with concurrent restriction but without persistent opacities. Eleven percent of 174 bilateral lung transplant recipients with CLAD were found to have an undefined phenotype in one single-center study [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unclassified CLAD</strong> – When ISHLT criteria are applied stringently to a cohort of CLAD patients, some patients may remain unclassified [<a href="#rid1">1,5</a>], up to 15 percent in one study of bilateral lung transplant recipients. It is possible that these patients have some other underlying process that cannot be identified with our current clinical tools.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLAD phenotypes in single-lung transplant recipients</strong> – Most studies that assessed CLAD phenotyping have been performed in bilateral lung transplant recipients, where pulmonary function tests (PFTs) reflect both allografts. However, in single-lung transplant recipients, where PFTs are a combined representation of the allograft and the native lung, interpretation of clinical data is more challenging [<a href="#rid6">6</a>]. One recent study found that 22 percent of 105 single-lung transplant recipients with CLAD had undefined phenotype [<a href="#rid7">7</a>]. Another study diagnosed 3 percent of 67 single-lung transplant recipients with CLAD with undefined phenotype and 28.3 percent remained unclassified [<a href="#rid6">6</a>]. The latter study of single-lung transplant recipients showed a poor interrater agreement for CLAD phenotypes but a significantly better agreement on the presence of chest CT opacities [<a href="#rid6">6</a>], suggesting that radiologic criteria are more reliable in these patients.</p><p></p><p>Other types of allograft rejection, such as acute cellular rejection and humoral rejection, typically occur earlier after transplantation and are discussed separately. (See  <a class="medical medical_review" href="/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection"</a> and  <a class="medical medical_review" href="/d/html/16926.html" rel="external">"Evaluation and treatment of antibody-mediated lung transplant rejection"</a>.)</p><p class="headingAnchor" id="H23527375"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>CLAD is a major source of long-term morbidity after lung and heart-lung transplantation. The exact incidence is uncertain, in part because of inconsistent definitions used among the various reports and different lengths of follow-up. Because the occurrence of BOS increases over time, centers with a longer experience report higher rates, particularly in their later publications. The largest experience, from the International Society for Heart and Lung Transplant (ISHLT) registry, reports that 50 percent of recipients develop BOS by five years after lung transplant and 74 percent after ten years (<a class="graphic graphic_figure graphicRef54760" href="/d/graphic/54760.html" rel="external">figure 3</a>) [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H6085992"><span class="h1">ETIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>The etiology of CLAD remains to be defined. Some evidence suggests that CLAD is a manifestation of a chronic alloimmune response and airway-centered rejection. However, events other than chronic rejection may also contribute. It may be more accurate to view CLAD as the final common pathway of a number of insults, including some that are not purely alloimmune, such as infection and aspiration [<a href="#rid1">1</a>]. Of note, most studies of etiology and risk factors have not differentiated between restrictive allograft syndrome (RAS) and BOS. </p><p>Many possible risk factors for the development of BO/BOS following lung transplantation have been proposed [<a href="#rid9">9-14</a>]. A panel of experts organized by the International Society for Heart and Lung Transplantation (ISHLT) and subsequent studies have categorized various risk factors as probable or possible (<a class="graphic graphic_table graphicRef52692" href="/d/graphic/52692.html" rel="external">table 2</a>) [<a href="#rid12">12,13,15</a>]. Medication noncompliance is listed as risk factor, perhaps due to erratic immunosuppressive drug levels [<a href="#rid16">16</a>] and an associated increase in acute rejection. The following factors are considered probable or potential contributors to CLAD:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic rejection</strong> – Evidence suggesting that BOS is a manifestation of chronic rejection comes from a number of observations [<a href="#rid17">17-20</a>]. </p><p></p><p class="bulletIndent1">Development of donor specific antibodies (DSA) that recognize donor human leukocyte antigens (HLA), most commonly DQ, has been documented in patients with BOS [<a href="#rid19">19-21</a>]. The development of DSA may precede the development of BOS and de novo development of HLA antibodies, particularly to HLA-DQ antigens, correlates with the loss of pulmonary function [<a href="#rid22">22-26</a>]. An increasing number of HLA mismatches between graft and host, particularly mismatches at the HLA-DQ locus, are associated with an enhanced risk of BOS [<a href="#rid10">10,27-30</a>].</p><p></p><p class="bulletIndent1">Finally, the histopathology and clinical presentation of obliterative bronchiolitis (OB) in lung transplant recipients closely resembles the pulmonary manifestations of graft-versus-host disease after bone marrow transplantation, both histologically and clinically [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Lung'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute rejection</strong> – Episodes of acute rejection have been identified as a risk factor for BOS. In particular, recurrent episodes of acute rejection have been identified as a major risk factor in a number of retrospective epidemiologic analyses [<a href="#rid9">9,32-34</a>]. Other studies have found that more severe episodes of acute rejection, and those episodes manifesting with lymphocytic bronchiolitis, are associated with particularly high risk for BOS [<a href="#rid35">35,36</a>]. Even a single episode of mild rejection has been associated with an increased risk of CLAD [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection"</a> and  <a class="medical medical_review" href="/d/html/16926.html" rel="external">"Evaluation and treatment of antibody-mediated lung transplant rejection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral infection</strong> – In the nontransplant setting, OB is a well-described result of viral infections; several studies suggest that viral illness may contribute to BOS onset in the transplant setting as well.</p><p></p><p class="bulletIndent1">Retrospective analyses have demonstrated that cytomegalovirus (CMV) infection may be a risk factor for BOS in lung transplant recipients [<a href="#rid27">27,29,38</a>], although this was not found in all studies [<a href="#rid39">39</a>]. At a single center, 231 lung transplant recipients who received CMV-prophylaxis for the first 4 to 14 weeks posttransplant were prospectively followed for development of CMV pneumonitis and BOS [<a href="#rid40">40</a>]. Development of CMV pneumonitis within the first six months was associated with a significantly increased risk of BOS (hazard ratio 2.19; 95% CI 1.36-3.51). In a separate study, CLAD was associated with CMV infection that led to expression of certain virally encoded UL40 peptide variants [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p></p><p class="bulletIndent1">Community respiratory viral infections may contribute to CLAD [<a href="#rid42">42,43</a>]. In a study of 139 lung transplant recipients that prospectively monitored community-acquired respiratory viral (CARV) infections, the risk of CLAD was increased among those with CARV pneumonia (HR 3.94, 95% CI 1.97-7.90) [<a href="#rid42">42</a>]. Moreover, CARV without pneumonia was also associated with BOS in a study of 100 lung recipients [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/13952.html" rel="external">"Viral infections following lung transplantation", section on 'Community respiratory viruses'</a>.)</p><p></p><p class="bulletIndent1">Other viruses, such as herpes virus 6 and Epstein Barr virus have been associated with an increased risk of BOS in some, but not all studies [<a href="#rid44">44-46</a>]. Early experience suggests that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) increases risk of CLAD. Among lung transplant recipients with coronavirus disease 2019 (COVID-19) pneumonia, over 10 percent were diagnosed with CLAD at six months after acute infection [<a href="#rid47">47</a>]. Lastly, invasive fungal infections after lower respiratory viral infections appears to increase the risk of CLAD [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial and fungal infection and colonization</strong> – Isolation of pathogens such as <em>Aspergillus fumigatus</em> [<a href="#rid49">49</a>] and <em>Pseudomonas aeruginosa</em> [<a href="#rid50">50-52</a>] have been associated with a higher incidence of chronic lung rejection. While the causal relationship remains to be determined (that is, does early chronic rejection predispose to airway colonization via impaired host defense, or does colonization incite an immune response that contributes to bronchiolitis), these observations suggest that identification and treatment of colonization may be of merit in preventing the progression of chronic rejection, in addition to potentially reducing the risk of invasive distal airspace infection.<strong> </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary graft dysfunction</strong> (PGD), a multifactorial injury to the transplanted lung that develops in the first 72 hours after transplantation, is associated with later development of BO, and the severity of initial PGD correlates with the risk of BO [<a href="#rid15">15,53,54</a>]. The mechanism for such an association is hypothesized to be due to oxidative damage, impairment of nitric oxide synthesis by pulmonary endothelial cells, and/or upregulation of HLA class II antigens on the allograft leading to production of donor specific HLA antibodies [<a href="#rid55">55-58</a>]. (See  <a class="medical medical_review" href="/d/html/4663.html" rel="external">"Primary lung graft dysfunction"</a> and  <a class="medical medical_review" href="/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation", section on 'Steps to optimize lung preservation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastroesophageal reflux</strong> (GER) is common in patients prior to and following lung transplantation and may contribute to chronic allograft rejection via acid or alkaline aspiration [<a href="#rid59">59-64</a>]. (See  <a class="medical medical_review" href="/d/html/4657.html" rel="external">"Physiologic changes following lung transplantation", section on 'Oropharyngeal dysphagia, gastroesophageal reflux, and gastroparesis'</a>.)</p><p></p><p class="bulletIndent1">The frequency and clinical importance of GER were evaluated in a report of 128 lung transplant recipients at a single institution; 93 (73 percent) had abnormal esophageal acid contact times based upon 24 hour ambulatory pH probe monitoring [<a href="#rid59">59</a>]. From this group, 26 patients met diagnostic criteria for BOS and underwent fundoplication. Following the procedure, 16 had lower BOS scores, and 13 no longer met criteria for the diagnosis of BOS. Long-term follow-up of these patients suggests that early fundoplication may result in a lower incidence of BOS and improved survival [<a href="#rid59">59,63</a>]. In addition, a retrospective cohort study suggests that impedance analysis provides useful predictive value in addition to pH testing [<a href="#rid65">65</a>]. </p><p></p><p class="bulletIndent1">However, in a large observational cohort of 149 patients who underwent laparoscopic fundoplication (LF) for positive esophageal pH studies after lung transplant, LF largely did not affect lung function or lung function trajectory [<a href="#rid66">66</a>]. Although a small number of patients demonstrated improved lung function (9 percent) in the 12 months after LF, a larger number demonstrated a decline (13 percent).</p><p></p><p class="bulletIndent1">The retrospective nature and size of these studies are insufficient to establish a clear causal relationship between GER and BOS. ISHLT guidelines suggest that GER should be treated aggressively following lung transplantation [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/d/html/2265.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transplant type</strong> – Single rather than double lung transplantation may also be a risk factor for BO (at least among patients with chronic obstructive pulmonary disease [COPD], although progression of COPD in the remaining native lung may be a confounding factor in measurement of airflow limitation) (see <a class="local">'Pulmonary function testing'</a> below). In a retrospective study of 221 patients who received lung transplantation due to end-stage COPD, double lung transplant recipients were more likely to be free from BOS than single lung transplant recipients three years (57 versus 51 percent) and five years (45 versus 18 percent) after transplantation [<a href="#rid67">67</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmunity and pre-transplant alloimmunity</strong> – An emerging theory concerning the pathobiology of bronchiolitis obliterans is that it could result from autoimmunity (in addition to alloimmunity) to usually hidden epitopes of collagen type V that are presumably exposed as a result of ischemia/reperfusion injury or other insults that damage the allograft airway epithelium [<a href="#rid11">11</a>]. Moreover, increasing evidence suggests that patients with pre-existing antibodies to HLA or major histocompatibility complex (MHC) class I chain-related gene A antigens are associated with a higher risk of developing BOS after transplantation [<a href="#rid68">68</a>]. </p><p></p><p class="headingAnchor" id="H12"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The symptoms associated with the development of BOS are nonspecific and include dyspnea on exertion and a nonproductive cough (<a class="graphic graphic_table graphicRef58663" href="/d/graphic/58663.html" rel="external">table 3</a>). Patients may present with a syndrome resembling an upper respiratory tract infection. It is not known whether such a presentation reflects an etiologic role of viral infection or the nonspecific nature of the symptoms. Alternatively, patients may simply present with subtle increases in exertional dyspnea and a decline in spirometry. It is unusual for BOS to begin less than three months after transplant, and the onset is typically more indolent than that of acute rejection. In the early stages of BOS, the physical examination is typically normal.</p><p>The more advanced stages of BOS are associated with dyspnea at rest and in some patients, symptoms and signs of bronchiectasis, including a productive cough and an abnormal chest examination with end-inspiratory pops and squeaks (<a class="graphic graphic_table graphicRef58663" href="/d/graphic/58663.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H23527297"><span class="h1">EVALUATION FOR CLAD</span><span class="headingEndMark"> — </span>Lung transplant recipients presenting with new onset of shortness of breath or cough or an acute decrease in lung function more than three months after lung transplantation should be evaluated for possible CLAD (<a class="graphic graphic_algorithm graphicRef143018" href="/d/graphic/143018.html" rel="external">algorithm 1</a>). In addition, lung transplant recipients should be routinely evaluated for CLAD as part of ongoing monitoring, which generally includes regular spirometric monitoring and clinical assessment. </p><p>The exact frequency of follow-up is determined by the individual centers and the clinical stability of the patient. A reasonable protocol is to obtain lab testing and formal spirometry monthly for at least the first year. For patients who do well, the interval may be extended to every two to three months in subsequent years. (See  <a class="medical medical_review" href="/d/html/16734.html" rel="external">"Maintenance immunosuppression following lung transplantation", section on 'Monitoring and adjusting maintenance therapy'</a>.)</p><p class="headingAnchor" id="H23527355"><span class="h2">Laboratory</span><span class="headingEndMark"> — </span>No laboratory tests have been identified that are diagnostic for CLAD. When evaluating a patient for possible CLAD, the patient’s ongoing immunosuppression is assessed by checking drug levels as appropriate for the patient’s maintenance immunosuppressive regimen.</p><p>Depending on the clinical suspicion for infection, other tests may be performed such as complete blood count and differential, sputum gram stain and culture, cytomegalovirus PCR, serum cryptococcal antigen, other viral cultures/immunoassays, urine enzyme immunoassay (EIA) for <em>Histoplasma</em> antigen, serum galactomannan antigen, and legionella urinary antigen. Screening for de novo HLA antibodies to donor antigens should be performed. (See  <a class="medical medical_review" href="/d/html/16734.html" rel="external">"Maintenance immunosuppression following lung transplantation", section on 'Monitoring and adjusting maintenance therapy'</a> and  <a class="medical medical_review" href="/d/html/13952.html" rel="external">"Viral infections following lung transplantation"</a> and  <a class="medical medical_review" href="/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation"</a> and  <a class="medical medical_review" href="/d/html/1394.html" rel="external">"Fungal infections following lung transplantation"</a> and  <a class="medical medical_review" href="/d/html/16926.html" rel="external">"Evaluation and treatment of antibody-mediated lung transplant rejection"</a>.)</p><p>Patients with bronchiectasis due to advanced CLAD-BOS often grow <em>Pseudomonas</em> in their sputum cultures. It remains unclear whether <em>Pseudomonas</em> colonization contributes to BOS or merely results from allograft dysfunction and defects in host defense. </p><p class="headingAnchor" id="H23527290"><span class="h2">Pulmonary function testing</span><span class="headingEndMark"> — </span>The key feature of BOS is airflow limitation, so pulmonary function testing, particularly spirometry, is a standard method for monitoring lung transplant recipients (<a class="graphic graphic_algorithm graphicRef143018" href="/d/graphic/143018.html" rel="external">algorithm 1</a>). Most centers use routine home spirometry, but long-term patient compliance with this modality is inconsistent. Additional testing with measurement of lung volumes and diffusing capacity are guided by the results of spirometry. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p>In order to monitor for new onset airflow limitation, a "baseline value" is ascertained after lung transplantation, by taking the mean of the two highest values of forced expiratory volume in one second (FEV<sub>1</sub>) obtained at least three weeks apart and without preceding bronchodilator inhalation [<a href="#rid12">12</a>]. If FEV<sub>1</sub> improves with a longer postoperative time, the baseline value is recalculated with the higher value. The ISHLT consensus report advises measuring total lung capacity (TLC) by body plethysmography at three and six months after transplant to obtain a new baseline and annually thereafter [<a href="#rid1">1</a>]. If FEV<sub>1</sub> changes by ≥10 percent, the TLC should be reassessed.</p><p>The spirometric pattern of BOS is airflow limitation with a decrease in FEV<sub>1</sub> from the postsurgical baseline and in the FEV<sub>1</sub>/forced vital capacity (FVC) ratio. A declining forced expiratory flow 25-75 percent (FEF 25-75) can be a clue to evolving BOS. TLC is typically normal or increased due to air trapping. CLAD severity is based on the degree of decline in FEV<sub>1</sub> as described below [<a href="#rid1">1</a>]. (See <a class="local">'CLAD staging (severity)'</a> below.)</p><p>As BOS is defined as persistent, otherwise unexplained, airflow limitation, patients are not considered to have BOS until two sets of spirometry obtained at least three weeks apart show a significant decrease from baseline. However, most centers will initiate investigation for CLAD if the FEV<sub>1</sub> decreases by ≥10 percent from baseline (CLAD 0) [<a href="#rid1">1</a>]. Once the criteria for BOS have been met, the stage of BOS thereafter is determined by the most recent value of FEV<sub>1</sub>. </p><p>The results of spirometry from single lung transplant recipients may be more difficult to interpret, particularly if the underlying lung disease in the native lung was obstructive (eg, chronic obstructive pulmonary disease [COPD], panbronchiolitis) [<a href="#rid69">69</a>]. (See <a class="local">'Other phenotypes'</a> above.)</p><p>By consensus, the determination of BOS is based on a percent (rather than absolute) decline in FEV<sub>1</sub> from the highest posttransplant value regardless of whether the patient had a single or bilateral lung transplant.</p><p>Bronchial hyperresponsiveness to <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> is common following lung transplantation and does not appear to be a useful predictor of the development of BOS [<a href="#rid70">70</a>], although earlier studies suggested otherwise [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/d/html/525.html" rel="external">"Bronchoprovocation testing"</a>.)</p><p class="headingAnchor" id="H23527305"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Chest imaging studies have a low sensitivity for identification of BO/BOS and are not used for screening. On the other hand, virtually all lung transplant recipients who present with new onset or worsening shortness of breath or other respiratory symptoms or signs or a decline in FEV<sub>1</sub> of 10 percent or greater should have a chest radiograph. In the early stages of BO, the chest radiograph is typically unchanged compared with the posttransplantation baseline. In more advanced disease, the chest radiograph can demonstrate areas of hyperinflation and possibly bronchiectasis [<a href="#rid72">72,73</a>].</p><p>ISHLT consensus report on CLAD advises obtaining a high-resolution computed tomography (HRCT) scan (inspiratory views with a maximum width of 3-mm sections, and expiratory images as well) six months posttransplant as a new baseline for future comparisons [<a href="#rid1">1</a>]. The role of HRCT in identification of early BOS is unclear, but many transplant pulmonologists obtain HRCT as part of the initial evaluation of declining lung function after transplant (<a class="graphic graphic_algorithm graphicRef143018" href="/d/graphic/143018.html" rel="external">algorithm 1</a>). HRCT may identify bronchial stenosis or other causes of decline, such as subclinical infection, fluid overload, or pleural effusion. The presence of parenchymal opacities and/or increasing pleural thickening is suggestive of RAS rather than BOS. Bronchiectasis can be present in later phases of BOS, but also can be due to traction effects in patients with RAS [<a href="#rid1">1</a>]. Thus, bronchiectasis can be present in patients with BOS, RAS, or a mixed phenotype. (See <a class="local">'CLAD phenotypes'</a> above.)</p><p class="headingAnchor" id="H23527792"><span class="h2">Flexible bronchoscopy</span><span class="headingEndMark"> — </span>For patients with spirometric findings suggestive of BOS, bronchoscopy may be useful to exclude other airway abnormalities that can cause airflow limitation on spirometry, such as anastomotic site stenosis or endobronchial tumor. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchoalveolar lavage (BAL)</strong> – BAL is typically performed to exclude infection (eg, bacterial, viral, fungal) or malignancy as a cause of deteriorating lung function. For patients with a new opacity on chest imaging, BAL is performed in the affected area, and samples are sent for cell counts and differential, microbiologic stains and cultures, viral testing (eg, immunoassay or polymerase chain reaction), and cytology (eg, malignancy, <em>Pneumocystis</em>, fungus). (See  <a class="medical medical_review" href="/d/html/4303.html" rel="external">"Basic principles and technique of bronchoalveolar lavage"</a>.)</p><p></p><p class="bulletIndent1">The BAL findings in patients with CLAD are nonspecific. Among stable lung transplant recipients undergoing routine monitoring with BAL and transbronchial biopsy, BAL neutrophilia was noted in those with biopsies showing higher grade lymphocytic bronchiolitis, suggestive of obliterative bronchiolitis (OB) [<a href="#rid74">74</a>]. However, a neutrophilic BAL fluid (eg, 25 to 50 percent neutrophils) is common in the first three months following transplantation [<a href="#rid74">74</a>]. The cause of BAL neutrophilia in OB is not known. Possible explanations include gastroesophageal reflux with aspiration, bacterial colonization or infection in areas of bronchiectasis proximal to the narrowed areas of OB, and neutrophilic infiltration of alveolar or bronchiolar walls.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transbronchial biopsy</strong> – In general, our practice is to perform transbronchial biopsy when a diagnosis of CLAD is suspected on the basis of symptoms, a decline in FEV<sub>1</sub> (eg, 10 percent or greater) on spirometry, and/or chest imaging (<a class="graphic graphic_algorithm graphicRef143018" href="/d/graphic/143018.html" rel="external">algorithm 1</a>). The biopsy is used to identify evidence of OB or acute cellular rejection, or recurrence of an original lung disease such as sarcoid, but is often not useful for the definitive diagnosis of CLAD due to sampling issues and a variable yield [<a href="#rid1">1,33,75-77</a>]. However, in patients with advanced airflow obstruction, the morbidity of the biopsy outweighs its utility, and we do not perform it under these circumstances. (See  <a class="medical medical_review" href="/d/html/128271.html" rel="external">"Chronic lung allograft dysfunction: Restrictive allograft syndrome"</a> and  <a class="medical medical_review" href="/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection", section on 'Flexible bronchoscopy'</a>.)</p><p></p><p class="headingAnchor" id="H3370320205"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>While biopsy is not necessary to make a diagnosis of CLAD, lung biopsy is typically obtained to exclude other causes of lung function decline. Occasionally, biopsy will confirm clinical suspicion by revealing the predominant histopathologic manifestation of CLAD-BOS in the airways, fibrotic obliteration of bronchi (also called OB) [<a href="#rid1">1,78</a>]. The pathologic findings associated with OB are assessed in the C grade (C0: bronchiolitis obliterans absent or C1: bronchiolitis obliterans present) of the biopsy grading report described in the table (<a class="graphic graphic_table graphicRef61800" href="/d/graphic/61800.html" rel="external">table 4</a>) [<a href="#rid78">78</a>].</p><p>The early lesions of OB are submucosal lymphocytic inflammation and disruption of the epithelium of small airways (<a class="graphic graphic_picture graphicRef67871" href="/d/graphic/67871.html" rel="external">picture 1</a>) [<a href="#rid1">1,64,79</a>]. These are followed by an in-growth of fibromyxoid granulation tissue into the airway lumen, resulting in partial or complete obstruction (<a class="graphic graphic_picture graphicRef76542" href="/d/graphic/76542.html" rel="external">picture 2</a>). Granulation tissue then organizes in a stereotypical cicatricial pattern with resultant obliteration of the lumen of the airway (<a class="graphic graphic_picture graphicRef51639" href="/d/graphic/51639.html" rel="external">picture 3</a>). In some instances, the only residual histologic evidence of small airways is found on elastin stains, which demonstrate a ring of circumferential elastin around an otherwise undetectable airway (vanishing airways disease) [<a href="#rid80">80</a>]. </p><p>The term bronchiolitis obliterans should only be used when histology demonstrates dense fibrous scar tissue affecting the small airways. The presence of a lymphocytic submucosal infiltrate or intraluminal granulation tissue (without fibrous scarring) is not sufficient for a diagnosis of CLAD but is highly suggestive [<a href="#rid12">12</a>].</p><p>In contrast, the characteristic histopathology of RAS includes parenchymal and pleural changes, with alveolar damage and fibrosis of the alveolar interstitium and interlobular septa and visceral pleural fibroelastosis with or without obliterative bronchiolitis lesions [<a href="#rid3">3,81,82</a>]. (See  <a class="medical medical_review" href="/d/html/128271.html" rel="external">"Chronic lung allograft dysfunction: Restrictive allograft syndrome", section on 'Pathology'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of CLAD due to BOS is based on a ≥20 percent decline in forced expiratory volume in one second (FEV<sub>1</sub>) that is persistent for three months after the first value is obtained, a normal or increased total lung capacity, and absence of new pulmonary opacities (<a class="graphic graphic_algorithm graphicRef143018" href="/d/graphic/143018.html" rel="external">algorithm 1</a>) [<a href="#rid1">1</a>]. The decrease in FEV<sub>1</sub> should be without other explanation (eg, acute cellular/antibody-mediated rejection, infection, airway stenosis, or tracheomalacia). </p><p>At the time of the first abnormal value, CLAD is considered "probable"; after three months without improvement, CLAD is considered "confirmed" [<a href="#rid1">1</a>]. If the FEV<sub>1</sub> returns to the baseline value after therapy, the diagnosis of CLAD is not sustained (See <a class="local">'Definition'</a> above.).</p><p>For most lung transplant recipients, the underlying presence of obliterative bronchiolitis (OB) is assumed but usually is not confirmed by biopsy. (See <a class="local">'Definition'</a> above and <a class="local">'Histopathology'</a> above.)</p><p>The diagnosis of CLAD due to restrictive allograft syndrome (RAS) relies heavily on high-resolution computed tomography (HRCT). RAS develops over approximately the same time frame as BOS and is characterized by restrictive physiology and peripheral lung fibrosis [<a href="#rid3">3,83-86</a>]. The typical chest HRCT shows increased reticular opacities, predominantly in the upper lung zones, and traction bronchiectasis [<a href="#rid81">81,87</a>]. Pathologic examination shows fibrosis in the alveolar septa, visceral pleura, and scattered obliterative bronchiolitis lesions [<a href="#rid81">81</a>]. Patients frequently experience episodes of acute exacerbation with patchy or diffuse ground-glass opacities on the chest CT and diffuse alveolar damage on lung biopsy [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/d/html/128271.html" rel="external">"Chronic lung allograft dysfunction: Restrictive allograft syndrome"</a>.)</p><p class="headingAnchor" id="H1391546015"><span class="h1">CLAD STAGING (SEVERITY)</span><span class="headingEndMark"> — </span>CLAD severity is based on the degree of decline in FEV<sub>1</sub> and applies to both BOS and RAS [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>CLAD 0: Current FEV<sub>1</sub> &gt;80 percent of FEV<sub>1</sub> baseline</p><p class="bulletIndent1"><span class="glyph">●</span>CLAD 1: Current FEV<sub>1</sub> &gt;65 to 80 percent of FEV<sub>1</sub> baseline</p><p class="bulletIndent1"><span class="glyph">●</span>CLAD 2: Current FEV<sub>1</sub> &gt;50 to 65 percent of FEV<sub>1</sub> baseline</p><p class="bulletIndent1"><span class="glyph">●</span>CLAD 3: Current FEV<sub>1</sub> &gt;35 to 50 percent of FEV<sub>1</sub> baseline</p><p class="bulletIndent1"><span class="glyph">●</span>CLAD 4: Current FEV<sub>1</sub> ≤35 percent of FEV<sub>1</sub> baseline</p><p></p><p class="headingAnchor" id="H23527738"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of CLAD includes airway complications of lung transplantation, progression or recurrence of the underlying lung disease, acute cellular or antibody-mediated allograft rejection, and infection. These can usually be distinguished by the evaluation described above. (See <a class="local">'Evaluation for CLAD'</a> above and  <a class="medical medical_review" href="/d/html/4656.html" rel="external">"Noninfectious complications following lung transplantation"</a> and  <a class="medical medical_review" href="/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation"</a> and  <a class="medical medical_review" href="/d/html/1394.html" rel="external">"Fungal infections following lung transplantation"</a> and  <a class="medical medical_review" href="/d/html/13952.html" rel="external">"Viral infections following lung transplantation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Airway complications</strong> – Lung transplant recipients are at risk of airway complications, such as bronchial stenosis, granulation tissue, and tracheobronchomalacia, at the site of the bronchial anastomoses. Generally, the diagnosis is made via high-resolution computed tomography (HRCT) or airway inspection during flexible bronchoscopy. (See  <a class="medical medical_review" href="/d/html/4662.html" rel="external">"Airway complications after lung transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progression or recurrence of the underlying lung disease</strong> – Several lung diseases that can lead to lung transplantation have been reported to progress in the native lung in single lung transplant recipients (eg, chronic obstructive pulmonary disease [COPD]) and others may recur in the allograft (eg, diffuse panbronchiolitis, Langerhans cell histiocytosis, lymphangioleiomyomatosis, sarcoidosis). (See  <a class="medical medical_review" href="/d/html/4656.html" rel="external">"Noninfectious complications following lung transplantation", section on 'Recurrent primary disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute cellular rejection</strong> – Acute cellular rejection may be associated with a decrease in the forced expiratory volume in one second (FEV<sub>1</sub>), similar to BOS. However, the likelihood of acute cellular rejection decreases beyond the first 6 to 12 months, while the likelihood of BOS increases over time. The pathologic appearance is also different; acute airway-centered cellular rejection is associated with a lymphocytic bronchiolitis on biopsy rather than the dense fibrous scarring of BO. (See  <a class="medical medical_review" href="/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection", section on 'Evaluation of symptomatic patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other restrictive processes (for those with possible RAS)</strong> – For patients with a decreased FEV<sub>1</sub>, but normal FEV<sub>1</sub>/forced vital capacity (FVC), the differential diagnosis focuses on diseases that cause a restrictive ventilatory defect, such as an increase in body mass index, muscular weakness (eg, diaphragmatic paralysis), pleural effusion, aging, or infection [<a href="#rid1">1,84</a>]. Evaluation includes physical examination for muscle weakness and weight gain; chest radiograph looking for pleural effusion, evidence of new interstitial lung disease, or airway occlusion; and also bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial lung biopsy. (See  <a class="medical medical_review" href="/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection"</a>.)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">TREATMENT OF BOS</span><span class="headingEndMark"> — </span>A variety of therapies have been tried for BOS, but there are no clinical trials or well-established protocols to guide therapy. Potential treatments include adding long-term <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (if not already used for prevention), changing the maintenance immunosuppressive medications, extracorporeal photopheresis, total lymphoid irradiation, plasmapheresis and other therapies to target antibodies to the allograft (<a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a>, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, proteasome inhibitors), and inhaled <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> (<a class="graphic graphic_table graphicRef64057" href="/d/graphic/64057.html" rel="external">table 5</a>) [<a href="#rid88">88-95</a>]. The decision among these choices depends on the severity of BOS, underlying immunosuppressive regimen, preferences of individual transplant centers, and response to treatment.</p><p class="headingAnchor" id="H5795281"><span class="h2">New onset BOS</span><span class="headingEndMark"> — </span>In the absence of clinical trial data to guide therapy for patients with new onset BOS, we typically add <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (if not already in place), review the maintenance immunosuppressive regimen for possible adjustment, and ensure that serum levels of the various immunosuppressive agents are appropriate (<a class="graphic graphic_table graphicRef60918" href="/d/graphic/60918.html" rel="external">table 6</a>). Response to therapy is assessed with ongoing measurement of spirometry. </p><p class="headingAnchor" id="H220879452"><span class="h3">Azithromycin</span><span class="headingEndMark"> — </span>For patients with a new diagnosis of BOS and no evidence of infection who are not already on <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> for prevention of BOS, we typically initiate oral azithromycin (generally 250 mg daily for five days, followed by 250 mg three times weekly) [<a href="#rid64">64,96</a>]. Preliminary reports suggest that prolonged oral azithromycin therapy may stop or reverse the decline in pulmonary function associated with BOS in some (but not all) patients [<a href="#rid62">62,97-105</a>]. While awaiting further data to guide decision-making, we generally continue azithromycin long-term, even in patients who do not have improvement in lung function. BOS tends to be progressive, so it is difficult to determine whether azithromycin is slowing progression in an individual patient. An alternative would be to discontinue azithromycin if BOS continues to progress after a minimum three-month trial period.</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 107 patients with BOS, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> treatment for three to six months (250 mg daily for five days, followed by 250 mg three times weekly) resulted in a 10 percent or greater increase in forced expiratory volume in one second (FEV<sub>1</sub>) in 40 percent of patients [<a href="#rid106">106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 81 lung transplant recipients with at least BOS stage 0p treated with <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> 250 mg three times a week, 24 showed an improvement in FEV<sub>1</sub>, whereas 35 showed disease progression [<a href="#rid101">101</a>]. The majority of responders were identified by three months of treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 62 patients with potential BOS or stage 1 to 3 BOS who were treated with <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (250 mg daily for five days, then 250 mg three times per week) for one year, 13 had a 10 percent or greater improvement in FEV<sub>1</sub>, 35 had stabilization, and 14 further deteriorated [<a href="#rid107">107</a>]. Those with potential BOS were more likely to respond to azithromycin than those with more advanced disease.</p><p></p><p>The macrolide <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> would theoretically be an alternative to <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> [<a href="#rid108">108</a>]; however, due to drug-drug interactions, azithromycin is generally preferred.</p><p class="headingAnchor" id="H3744120967"><span class="h3">Adjusting maintenance immunosuppression</span><span class="headingEndMark"> — </span>Some patients with early BOS have responded to changes in their maintenance immunosuppression regimen in favor of <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>. Thus, for patients on <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, we often substitute tacrolimus [<a href="#rid64">64,109</a>], and for patients on <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, we substitute mycophenolate. These choices are based on case series that reported success with these substitutions, and are not universally accepted [<a href="#rid110">110,111</a>]. As an example, a study of 32 patients with BO found that conversion from cyclosporine to tacrolimus was associated with slower rates of decline in spirometry over 12 months of follow-up and slightly better one-year survival [<a href="#rid112">112</a>]. A second study of 13 patients reported similar results when mycophenolate mofetil was substituted for azathioprine [<a href="#rid113">113</a>]. Other studies have reported similar results following substitutions in the immunosuppressive regimen [<a href="#rid114">114-116</a>]. (See  <a class="medical medical_review" href="/d/html/16734.html" rel="external">"Maintenance immunosuppression following lung transplantation", section on 'Monitoring and adjusting maintenance therapy'</a>.)</p><p class="headingAnchor" id="H5795296"><span class="h2">Progressive BOS</span><span class="headingEndMark"> — </span>For patients with a progressive decline in FEV<sub>1</sub> despite <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> and optimization of the maintenance immunosuppressive regimen, we choose among the following options based on a case-by-case evaluation. As an example, extracorporeal photopheresis requires insurance approval and frequent visits to the transplant center and may not be possible for patients who live at a distance. <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> are associated with bone marrow suppression and are often avoided in patients with significant cytopenias; they should be used with caution in patients with significant renal impairment.</p><p>The evidence in favor of various salvage therapies includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Montelukast</strong>, a leukotriene receptor antagonist, slowed decline in FEV<sub>1</sub> compared with control in an open-label study [<a href="#rid117">117</a>]. However, a small randomized trial did not support a survival benefit [<a href="#rid118">118</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sirolimus</strong><strong> and </strong><strong>everolimus</strong> are mTOR inhibitors that suppress T-lymphocyte activation and proliferation; they have a similar structure to the calcineurin inhibitors (<a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>) but exert their immunosuppressive effects through calcineurin-independent mechanisms. In an open label study, BOS was less likely to progress when <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> was substituted for <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> in 37 subjects receiving either cyclosporine or tacrolimus; however, side effects led to sirolimus discontinuation in 59 percent of patients [<a href="#rid119">119</a>]. The use of <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> has been reported in case series of lung transplant recipients, although the effect on BOS was inconclusive [<a href="#rid120">120,121</a>]. </p><p></p><p class="bulletIndent1">Development of BOS may be reduced or delayed among lung recipients taking <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> for maintenance immunosuppression, although data are limited [<a href="#rid122">122,123</a>]. <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> and everolimus are contraindicated within the first 90 days after lung transplant due to problems with dehiscence of the bronchial anastomosis. The use of mTOR inhibitors for maintenance immunosuppression and the dosing and adverse effects of these agents in lung recipients are discussed separately. (See  <a class="medical medical_review" href="/d/html/16734.html" rel="external">"Maintenance immunosuppression following lung transplantation", section on 'mTOR inhibitors'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extracorporeal psoralen photopheresis (ECP)</strong> reduced the rate of decline in lung function in the setting of BOS in single center experiences [<a href="#rid89">89-91,124-126</a>]. In extracorporeal photopheresis, peripheral blood lymphocytes are collected via apheresis, treated with 8-methoxypsoralen followed by exposure to a source of ultraviolet A light, and reinfused. This process is thought to act by inducing lymphocyte apoptosis and induction of T regulatory (Treg) cells. Among 51 patients with BOS treated with ECP (two successive days every two weeks for three months and then every four weeks), the FEV<sub>1</sub> improved or stabilized in 61 percent [<a href="#rid124">124</a>]. Those who responded to ECP had better survival and a lower rate of retransplantation than nonresponders. Clinical trials are in progress (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=4654" target="_blank">clinicaltrials.gov</a> NCT03500575 and NCT02181257). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Total lymphoid irradiation</strong> has been assessed in small observational studies in which the rate of decline in lung function was generally slower after irradiation than before [<a href="#rid92">92,93</a>]. However, in one study, 10 of 37 patients were unable to complete the therapy due to progressive BOS or bone marrow suppression [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aerosolized </strong><strong>cyclosporine</strong> demonstrated preliminary evidence of benefit in two single center reports [<a href="#rid88">88,127</a>] Multi-center, multi-national studies of liposomal <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> for early stage CLAD in single and double lung transplant recipients are in progress (NCT03657342 and NCT03656926). A separate case report described improvement in BOS with aerosolized <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid128">128</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antilymphocyte and antithymocyte therapies</strong> were evaluated in a series of 48 lung transplant recipients with BOS who received 64 courses of treatment with a cytolytic agent (antilymphocyte globulin, antithymocyte globulin, or muromononab-CD3 [OKT3] monoclonal antibody) [<a href="#rid129">129</a>]. The rate of decline in FEV<sub>1</sub> slowed in the three months after treatment, but BOS eventually progressed in all patients.</p><p></p><p class="headingAnchor" id="H5795538"><span class="h2">Less established or ineffective therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – While systemic glucocorticoids are the cornerstone of management of acute lung transplant rejection, they appear to have limited utility in the management of BOS [<a href="#rid1">1</a>]. High-dose inhaled glucocorticoids are included in regimens to treat bronchiolitis obliterans following hematopoietic cell transplantation (see  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Airflow obstruction and bronchiolitis obliterans'</a>). It is hoped that local delivery of the glucocorticoids will control the lymphocytic bronchiolitis seen on biopsies. However, a randomized trial did not find evidence that inhaled glucocorticoids slowed or prevented BOS, possibly due to insufficient power [<a href="#rid130">130</a>]. (See  <a class="medical medical_review" href="/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection", section on 'High-dose glucocorticoids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alemtuzumab</strong> – An open label study evaluating the anti-CD52 antibody <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> for BOS showed stabilization or improvement in the BOS grade in 7 of 10 patients [<a href="#rid131">131</a>]. In addition, a small retrospective study comparing alemtuzumab with extracorporeal photopheresis demonstrated a comparable improvement in the slope of FEV<sub>1 </sub>decline with either therapy compared with an untreated population, but no appreciable difference in infections or survival compared with an untreated population [<a href="#rid132">132</a>]. (See  <a class="medical medical_review" href="/d/html/4661.html" rel="external">"Induction immunosuppression following lung transplantation", section on 'Alemtuzumab'</a>.)</p><p></p><p class="headingAnchor" id="H3218511"><span class="h2">Retransplantation for refractory BOS</span><span class="headingEndMark"> — </span>The role of retransplantation after the development of chronic lung rejection is controversial. Registry data suggest that the retransplant outcome is not as good as with the first transplant [<a href="#rid133">133</a>]; however, several single center reports have demonstrated comparable outcomes with retransplantation in carefully selected candidates [<a href="#rid134">134-137</a>].  </p><p class="bulletIndent1"><span class="glyph">●</span>Among 29 patients who underwent retransplantation for CLAD between March 2010 and May 2016, one and five year survival rates were 89 and 64 percent, which compares with survival rates of 89 and 58 percent among 391 primary lung transplants performed at the same institution [<a href="#rid135">135</a>]. However, the rates of cardiopulmonary bypass, re-exploration for bleeding, and post-retransplant extracorporeal membrane oxygenation (ECMO) were higher in retransplant recipients, and the small sample size limits generalizability. Chronic lung rejection was the most common cause of death in both groups. </p><p></p><p class="bulletIndent1">Similarly, at a different center, for carefully selected retransplants from 2010 to 2016 using a protocol for less invasive surgery, early and mid-term survival was comparable to first time transplants [<a href="#rid136">136</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate study of 143 patients who underwent retransplantation at one of four large volume centers (2003 to 2013), the five-year survival was 51 percent among those retransplanted for BOS, compared with 28 percent for those retransplanted for restrictive CLAD [<a href="#rid134">134</a>]. BOS recurred in 30 percent of retransplant recipients. </p><p></p><p>Outcomes of retransplantation are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/4651.html" rel="external">"Lung transplantation: Procedure and postoperative management", section on 'Retransplantation'</a>.) </p><p>Candidates for retransplantation need to be carefully selected and meet most if not all general guidelines for a first lung transplant. Notably, dependence on mechanical ventilation at the time of retransplantation does not by itself appear to have a significant adverse effect on survival in patients being retransplanted for BOS [<a href="#rid138">138,139</a>]. (See  <a class="medical medical_review" href="/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a>.)</p><p>Opinions concerning the appropriateness of retransplantation vary widely, given the limited availability of donor lungs. Most centers have more potential first-time recipients than donors, and mortality on the waiting list is a significant problem. As a result of these considerations, transplant programs vary in policy concerning the availability of retransplantation as a therapeutic option. (See  <a class="medical medical_review" href="/d/html/4651.html" rel="external">"Lung transplantation: Procedure and postoperative management", section on 'Retransplantation'</a>.)</p><p class="headingAnchor" id="H17742669"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>BOS is usually progressive, although the rate of progression varies from one patient to another [<a href="#rid140">140,141</a>]. Some patients experience a rapid, relentless progression, some have stabilization after an initial rapid deterioration, and others experience a subtle onset and slow progression.</p><p>The mortality rate associated with CLAD ranges from 25 to 55 percent [<a href="#rid142">142,143</a>]. Among stages of CLAD, the risk of death increases approximately three-fold with each step higher [<a href="#rid142">142</a>]. Unfortunately, in many patients, CLAD results in progressive respiratory failure, similar to the initial lung disease for which the transplant was originally performed.</p><p class="headingAnchor" id="H639928952"><span class="h1">FUTURE DIRECTIONS</span></p><p class="headingAnchor" id="H3526342692"><span class="h2">Surrogate markers</span><span class="headingEndMark"> — </span>A major area of unmet need in lung transplantation is the identification of surrogate markers for early CLAD. A number of potential markers of early CLAD have been suggested, but none is used clinically. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Neutrophil-predominant bronchoalveolar lavage fluid with increased levels of interleukin (IL)-12 and/or IL-17 [<a href="#rid74">74,144-148</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of air trapping on chest computed tomography (CT) scan [<a href="#rid149">149-152</a>] </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated exhaled nitric oxide levels [<a href="#rid114">114,153,154</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Soluble CD30 levels [<a href="#rid155">155</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increase in circulating fibrocytes detected by flow cytometry [<a href="#rid156">156</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Donor-derived cell free DNA (deoxyribonucleic acid) in plasma early after transplant [<a href="#rid157">157,158</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endobronchial brush gene expression [<a href="#rid159">159</a>].</p><p></p><p>Although these findings should alert physicians to the possibility of early CLAD, none of these modalities is sensitive or specific enough to be used outside of well-designed trials [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H189652623"><span class="h2">Investigational therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Belatacept</strong> – <a class="drug drug_general" data-topicid="16790" href="/d/drug information/16790.html" rel="external">Belatacept</a> is an immunosuppressant that blocks a T-cell costimulation pathway and is approved by the US Food and Drug Administration for use in kidney transplant recipients. Although some case series have shown preliminary benefit in lung transplant recipients who are intolerant of calcineurin inhibitors, one pilot randomized trial in lung transplant recipients showed increased mortality with a belatacept-based regimen compared with a typical transplant regimen. (See  <a class="medical medical_review" href="/d/html/16734.html" rel="external">"Maintenance immunosuppression following lung transplantation", section on 'Belatacept'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasmapheresis</strong> – Plasmapheresis has been used to treat humoral lung transplant rejection but has not been formally studied in CLAD. (See  <a class="medical medical_review" href="/d/html/16926.html" rel="external">"Evaluation and treatment of antibody-mediated lung transplant rejection"</a> and  <a class="medical medical_review" href="/d/html/16926.html" rel="external">"Evaluation and treatment of antibody-mediated lung transplant rejection", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifibrotic agents</strong> – Based on the use of <a class="drug drug_general" data-topicid="88424" href="/d/drug information/88424.html" rel="external">pirfenidone</a> and <a class="drug drug_general" data-topicid="97640" href="/d/drug information/97640.html" rel="external">nintedanib</a> as anti-fibrotic agents for idiopathic and other forms of pulmonary fibrosis, there has been interest in evaluating their effects in CLAD-RAS. One trial (NCT03473340) was terminated early for slow enrollment.</p><p></p><p class="headingAnchor" id="H2054654924"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The best strategy to deal with chronic rejection is primary prevention, as there is no reliable therapy once patients develop symptomatic airflow obstruction. Potential interventions for prevention of BOS include aggressive initial immunosuppression to eliminate early episodes of acute cellular rejection, prophylaxis against cytomegalovirus (CMV) with oral <a class="drug drug_general" data-topicid="10058" href="/d/drug information/10058.html" rel="external">valganciclovir</a> in recipients who are at risk for CMV infection, vaccination against influenza and pneumococcus, reduction in cold ischemia time and other methods to reduce primary graft dysfunction, treatment of gastroesophageal reflux to reduce acid and alkaline aspiration, and long-term <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>.</p><p>Macrolide antibiotics are used in a variety of bronchiolar disorders (eg, panbronchiolitis, constrictive bronchiolitis) and are thought to act more through anti-inflammatory than antimicrobial mechanisms. The effect of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> in preventing BO was assessed in a randomized trial of 83 lung transplant recipients who received azithromycin 250 mg three times a week for two years. BOS developed in 12 percent of patients on azithromycin compared with 44 percent of those on placebo [<a href="#rid97">97</a>]. The overall survival between the groups was not different. Side effects related to chronic azithromycin therapy included nausea and diarrhea; one case of <em>Clostridioides</em> <em>difficile</em> pseudomembranous colitis occurred in the each of the active treatment and placebo groups.</p><p>Based on the accumulated data and clinical experience, it is reasonable to use <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> as prophylaxis against chronic rejection, although an impact on survival has not been demonstrated [<a href="#rid97">97,160</a>].</p><p>For patients who have <em>Pseudomonas aeruginosa</em> in their post-lung transplant respiratory secretions, preliminary evidence suggests that successful eradication with targeted antibiotic treatment may improve CLAD-free survival [<a href="#rid161">161</a>].</p><p>The role of induction and maintenance immunosuppression in prevention of CLAD is discussed separately. (See  <a class="medical medical_review" href="/d/html/4661.html" rel="external">"Induction immunosuppression following lung transplantation"</a> and  <a class="medical medical_review" href="/d/html/16734.html" rel="external">"Maintenance immunosuppression following lung transplantation"</a>.)</p><p class="headingAnchor" id="H2301188403"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122278.html" rel="external">"Society guideline links: Lung transplantation"</a>.)</p><p class="headingAnchor" id="H23526910"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – CLAD is defined as a substantial and persistent decline (≥20 percent) in forced expiratory volume in one second (FEV<sub>1</sub>) when compared with the posttransplant baseline. CLAD typically develops more than three months after transplant and can predominantly affect the airways (BOS) or the lung parenchyma (restrictive allograft syndrome [RAS]). (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The BOS subtype of CLAD, which is more common than RAS, is characterized by airflow limitation in the absence of other etiologies, with or more often without histologic evidence of obliterative bronchiolitis (OB) (<a class="graphic graphic_picture graphicRef67871" href="/d/graphic/67871.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef76542" href="/d/graphic/76542.html" rel="external">picture 2</a>). (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – The exact etiology of CLAD is unclear, but it is believed to be primarily a manifestation of chronic rejection of the allograft. Other potential contributory factors include primary graft dysfunction, recurrent and severe episodes of acute cellular rejection, cytomegalovirus and other viral infections, gastroesophageal reflux, and possibly autoimmunity. (See <a class="local">'Etiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The clinical presentation of CLAD is nonspecific with dyspnea on exertion, nonproductive cough, or asymptomatic decline in spirometry. Early on, the physical examination is typically normal. In more advanced stages, the chest examination usually reveals end-inspiratory pops and squeaks. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The usual approach to a lung transplant recipient presenting with dyspnea, nonproductive cough, and/or declining spirometry includes laboratory assessment of maintenance immunosuppression and infection, chest imaging, and flexible bronchoscopy (<a class="graphic graphic_algorithm graphicRef143018" href="/d/graphic/143018.html" rel="external">algorithm 1</a>). (See <a class="local">'Evaluation for CLAD'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>BOS is defined as persistent, otherwise unexplained, airflow limitation as assessed by spirometry. Most centers will initiate investigation for CLAD if the FEV<sub>1</sub> decreases by ≥10 percent from baseline (CLAD 0). (See <a class="local">'Pulmonary function testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In early CLAD-BOS, the chest radiograph and high-resolution computed tomography (HRCT) scan are clear, but in advanced disease can demonstrate bronchiectasis and hyperinflation. (See <a class="local">'Clinical presentation'</a> above and <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with spirometric findings suggestive of BOS, we typically perform bronchoscopy with bronchoalveolar lavage (BAL) and biopsy to exclude airway abnormalities, rule-out infections, and evaluate for acute rejection or original lung disease recurrence. (See <a class="local">'Flexible bronchoscopy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of CLAD-BOS can be made conditionally based on recurrent worsened airflow limitation on spirometry and exclusion of alternate explanations; histopathologic confirmation is not needed (<a class="graphic graphic_algorithm graphicRef143018" href="/d/graphic/143018.html" rel="external">algorithm 1</a>). The severity of BOS is determined based on the degree of airflow limitation. (See <a class="local">'Diagnosis'</a> above and <a class="local">'CLAD staging (severity)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of BOS includes airway complications of lung transplantation (eg, bronchial stenosis, tracheobronchomalacia), infection, other phenotypes of CLAD, and progression or recurrence of the underlying lung disease (eg, chronic obstructive pulmonary disease [COPD], diffuse panbronchiolitis, Langerhans cell histiocytosis, lymphangiomyomatosis). (See <a class="local">'Differential diagnosis'</a> above and <a class="local">'CLAD phenotypes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of new onset BOS</strong> – Limited clinical trial data are available to guide therapy for BOS. (See <a class="local">'Treatment of BOS'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with new onset CLAD/BOS, we suggest addition of long-term <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> therapy rather than other therapies (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The usual dose is 250 mg daily for five days, followed by 250 mg three times weekly. (See <a class="local">'New onset BOS'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who develop CLAD while on a maintenance immunosuppression regimen that includes <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, we suggest changing cyclosporine to <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients who develop CLAD on <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, we suggest substituting <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> for azathioprine (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We also ensure that serum levels of the various immunosuppressive agents are appropriate (<a class="graphic graphic_table graphicRef60918" href="/d/graphic/60918.html" rel="external">table 6</a>). (See <a class="local">'New onset BOS'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of progressive BOS</strong> – For patients with a progressive decline in FEV<sub>1</sub> despite <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> and optimization of the immunosuppressive regimen, the choice among the less well-established options is based on a case-by-case evaluation and the preferences of the local transplant team (<a class="graphic graphic_table graphicRef64057" href="/d/graphic/64057.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Potential immunomodulatory therapies include <a class="drug drug_general" data-topicid="9539" href="/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> or <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, extracorporeal photophoresis, total lymphoid irradiation, and antilymphocyte or antithymocyte therapy. (See <a class="local">'Progressive BOS'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients who develop respiratory failure due to BOS, retransplantation is an option. Candidates for retransplantation need to be carefully selected and meet most if not all general guidelines for a first lung transplant. (See <a class="local">'Retransplantation for refractory BOS'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – BOS is often progressive despite these interventions, although the rate of progression varies from one patient to another. The mortality rate is 25 to 55 percent. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H10944045"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge John Reilly, Jr, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant 2019; 38:493.</a></li><li><a class="nounderline abstract_t">Chambers DC, Cherikh WS, Harhay MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant 2019; 38:1042.</a></li><li><a class="nounderline abstract_t">Glanville AR, Verleden GM, Todd JL, et al. Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant 2019; 38:483.</a></li><li><a class="nounderline abstract_t">Verleden SE, Von Der Thüsen J, Van Herck A, et al. Identification and characterization of chronic lung allograft dysfunction patients with mixed phenotype: A single-center study. Clin Transplant 2020; 34:e13781.</a></li><li><a class="nounderline abstract_t">Levy L, Huszti E, Renaud-Picard B, et al. Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system. J Heart Lung Transplant 2020; 39:761.</a></li><li><a class="nounderline abstract_t">Berra G, Huszti E, Levy L, et al. Phenotyping CLAD after single lung transplant: Limits and prognostic assessment of the 2019 ISHLT classification system. J Heart Lung Transplant 2022; 41:599.</a></li><li><a class="nounderline abstract_t">Leuschner G, Lauseker M, Howanietz AS, et al. Longitudinal lung function measurements in single lung transplant recipients with chronic lung allograft dysfunction. J Heart Lung Transplant 2020; 39:1270.</a></li><li class="breakAll">The International Society for Heart and Lung Transplantation. International thoracic organ transplnat (TTX) registry data slides. 2019 Adult Lung Transplantation Statistics. https://ishltregistries.org/registries/slides.asp (Accessed on February 12, 2020).</li><li><a class="nounderline abstract_t">Keller CA, Cagle PT, Brown RW, et al. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation. Chest 1995; 107:973.</a></li><li><a class="nounderline abstract_t">Chalermskulrat W, Neuringer IP, Schmitz JL, et al. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest 2003; 123:1825.</a></li><li><a class="nounderline abstract_t">Sumpter TL, Wilkes DS. Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol 2004; 286:L1129.</a></li><li><a class="nounderline abstract_t">Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297.</a></li><li><a class="nounderline abstract_t">Xu X, Golden JA, Dolganov G, et al. Transcript signatures of lymphocytic bronchitis in lung allograft biopsy specimens. J Heart Lung Transplant 2005; 24:1055.</a></li><li><a class="nounderline abstract_t">Novick RJ, Stitt LW, Al-Kattan K, et al. Pulmonary retransplantation: predictors of graft function and survival in 230 patients. Pulmonary Retransplant Registry. Ann Thorac Surg 1998; 65:227.</a></li><li><a class="nounderline abstract_t">Whitson BA, Prekker ME, Herrington CS, et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant 2007; 26:1004.</a></li><li><a class="nounderline abstract_t">Gallagher HM, Sarwar G, Tse T, et al. Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival. J Heart Lung Transplant 2015; 34:1442.</a></li><li><a class="nounderline abstract_t">Yousem SA, Burke CM, Billingham ME. Pathologic pulmonary alterations in long-term human heart-lung transplantation. Hum Pathol 1985; 16:911.</a></li><li><a class="nounderline abstract_t">Duncan SR, Leonard C, Theodore J, et al. Oligoclonal CD4(+) T cell expansions in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 2002; 165:1439.</a></li><li><a class="nounderline abstract_t">SivaSai KS, Smith MA, Poindexter NJ, et al. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation 1999; 67:1094.</a></li><li><a class="nounderline abstract_t">Saini D, Weber J, Ramachandran S, et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant 2011; 30:624.</a></li><li><a class="nounderline abstract_t">Reinsmoen NL, Bolman RM, Savik K, et al. Are multiple immunopathogenetic events occurring during the development of obliterative bronchiolitis and acute rejection? Transplantation 1993; 55:1040.</a></li><li><a class="nounderline abstract_t">Jaramillo A, Smith MA, Phelan D, et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999; 67:1155.</a></li><li><a class="nounderline abstract_t">Morrell MR, Pilewski JM, Gries CJ, et al. De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation. J Heart Lung Transplant 2014; 33:1288.</a></li><li><a class="nounderline abstract_t">Tikkanen JM, Singer LG, Kim SJ, et al. De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation. Am J Respir Crit Care Med 2016; 194:596.</a></li><li><a class="nounderline abstract_t">Verleden SE, Vanaudenaerde BM, Emonds MP, et al. Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation. Eur Respir J 2017; 50.</a></li><li><a class="nounderline abstract_t">Ennis SL, Olsen N, Tong WWY, et al. Specific human leucocyte antigen-DQ risk epitope mismatches are associated with chronic lung allograft dysfunction after lung transplantation. Am J Transplant 2023; 23:1009.</a></li><li><a class="nounderline abstract_t">Kroshus TJ, Kshettry VR, Savik K, et al. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997; 114:195.</a></li><li><a class="nounderline abstract_t">Sundaresan S, Mohanakumar T, Smith MA, et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998; 65:648.</a></li><li><a class="nounderline abstract_t">Smith MA, Sundaresan S, Mohanakumar T, et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 1998; 116:812.</a></li><li><a class="nounderline abstract_t">Schulman LL, Weinberg AD, McGregor CC, et al. Influence of donor and recipient HLA locus mismatching on development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2001; 163:437.</a></li><li><a class="nounderline abstract_t">Philit F, Wiesendanger T, Archimbaud E, et al. Post-transplant obstructive lung disease ("bronchiolitis obliterans"): a clinical comparative study of bone marrow and lung transplant patients. Eur Respir J 1995; 8:551.</a></li><li><a class="nounderline abstract_t">Boehler A, Kesten S, Weder W, Speich R. Bronchiolitis obliterans after lung transplantation: a review. Chest 1998; 114:1411.</a></li><li><a class="nounderline abstract_t">Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110:4.</a></li><li><a class="nounderline abstract_t">Burton CM, Iversen M, Carlsen J, et al. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1. J Heart Lung Transplant 2009; 28:888.</a></li><li><a class="nounderline abstract_t">Husain AN, Siddiqui MT, Holmes EW, et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999; 159:829.</a></li><li><a class="nounderline abstract_t">Glanville AR, Aboyoun CL, Havryk A, et al. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med 2008; 177:1033.</a></li><li><a class="nounderline abstract_t">Hachem RR, Khalifah AP, Chakinala MM, et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation 2005; 80:1406.</a></li><li><a class="nounderline abstract_t">Keenan RJ, Lega ME, Dummer JS, et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 1991; 51:433.</a></li><li><a class="nounderline abstract_t">Tamm M, Aboyoun CL, Chhajed PN, et al. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004; 170:1120.</a></li><li><a class="nounderline abstract_t">Snyder LD, Finlen-Copeland CA, Turbyfill WJ, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181:1391.</a></li><li><a class="nounderline abstract_t">Vietzen H, Hartenberger S, Jaksch P, Puchhammer-Stöckl E. Association between chronic lung allograft dysfunction and human Cytomegalovirus UL40 peptide variants in lung-transplant recipients. J Heart Lung Transplant 2021; 40:900.</a></li><li><a class="nounderline abstract_t">Allyn PR, Duffy EL, Humphries RM, et al. Graft Loss and CLAD-Onset Is Hastened by Viral Pneumonia After Lung Transplantation. Transplantation 2016; 100:2424.</a></li><li><a class="nounderline abstract_t">Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005; 5:2031.</a></li><li><a class="nounderline abstract_t">Neurohr C, Huppmann P, Leuchte H, et al. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant 2005; 5:2982.</a></li><li><a class="nounderline abstract_t">Manuel O, Kumar D, Moussa G, et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009; 87:719.</a></li><li><a class="nounderline abstract_t">Engelmann I, Welte T, Fühner T, et al. Detection of Epstein-Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation. J Clin Virol 2009; 45:47.</a></li><li><a class="nounderline abstract_t">Roosma E, van Gemert JP, de Zwart AES, et al. The effect of COVID-19 on transplant function and development of CLAD in lung transplant patients: A multicenter experience. J Heart Lung Transplant 2022; 41:1237.</a></li><li><a class="nounderline abstract_t">Permpalung N, Liang T, Gopinath S, et al. Invasive fungal infections after respiratory viral infections in lung transplant recipients are associated with lung allograft failure and chronic lung allograft dysfunction within 1 year. J Heart Lung Transplant 2023; 42:953.</a></li><li><a class="nounderline abstract_t">Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9:1903.</a></li><li><a class="nounderline abstract_t">Gottlieb J, Mattner F, Weissbrodt H, et al. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med 2009; 103:743.</a></li><li><a class="nounderline abstract_t">Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008; 85:771.</a></li><li><a class="nounderline abstract_t">Gregson AL, Wang X, Weigt SS, et al. Interaction between Pseudomonas and CXC chemokines increases risk of bronchiolitis obliterans syndrome and death in lung transplantation. Am J Respir Crit Care Med 2013; 187:518.</a></li><li><a class="nounderline abstract_t">Fiser SM, Tribble CG, Long SM, et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002; 73:1041.</a></li><li><a class="nounderline abstract_t">Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007; 175:507.</a></li><li><a class="nounderline abstract_t">Kallio EA, Koskinen PK, Aavik E, et al. Role of nitric oxide in experimental obliterative bronchiolitis (chronic rejection) in the rat. J Clin Invest 1997; 100:2984.</a></li><li><a class="nounderline abstract_t">Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59:313.</a></li><li><a class="nounderline abstract_t">McDermott CD, Gavita SM, Shennib H, Giaid A. Immunohistochemical localization of nitric oxide synthase and the oxidant peroxynitrite in lung transplant recipients with obliterative bronchiolitis. Transplantation 1997; 64:270.</a></li><li><a class="nounderline abstract_t">Bharat A, Kuo E, Steward N, et al. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg 2008; 86:189.</a></li><li><a class="nounderline abstract_t">Davis RD Jr, Lau CL, Eubanks S, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003; 125:533.</a></li><li><a class="nounderline abstract_t">King BJ, Iyer H, Leidi AA, Carby MR. Gastroesophageal reflux in bronchiolitis obliterans syndrome: a new perspective. J Heart Lung Transplant 2009; 28:870.</a></li><li><a class="nounderline abstract_t">Bobadilla JL, Jankowska-Gan E, Xu Q, et al. Reflux-induced collagen type v sensitization: potential mediator of bronchiolitis obliterans syndrome. Chest 2010; 138:363.</a></li><li><a class="nounderline abstract_t">Verleden SE, Vos R, Mertens V, et al. Heterogeneity of chronic lung allograft dysfunction: insights from protein expression in broncho alveolar lavage. J Heart Lung Transplant 2011; 30:667.</a></li><li><a class="nounderline abstract_t">Hartwig MG, Anderson DJ, Onaitis MW, et al. Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux. Ann Thorac Surg 2011; 92:462.</a></li><li><a class="nounderline abstract_t">Meyer KC, Raghu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J 2014; 44:1479.</a></li><li><a class="nounderline abstract_t">Lo WK, Burakoff R, Goldberg HJ, et al. Pre-lung transplant measures of reflux on impedance are superior to pH testing alone in predicting early allograft injury. World J Gastroenterol 2015; 21:9111.</a></li><li><a class="nounderline abstract_t">Frankel A, Kellar T, Zahir F, et al. Laparoscopic fundoplication after lung transplantation does not appear to alter lung function trajectory. J Heart Lung Transplant 2023; 42:603.</a></li><li><a class="nounderline abstract_t">Hadjiliadis D, Chaparro C, Gutierrez C, et al. Impact of lung transplant operation on bronchiolitis obliterans syndrome in patients with chronic obstructive pulmonary disease. Am J Transplant 2006; 6:183.</a></li><li><a class="nounderline abstract_t">Lyu DM, Grazia TJ, Benson AB, et al. Pre-transplant presence of antibodies to MICA and HLA class I or II are associated with an earlier onset of bronchiolitis obliterans syndrome in lung transplant recipients. Clin Transpl 2012; :237.</a></li><li><a class="nounderline abstract_t">Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J 2003; 22:1007.</a></li><li><a class="nounderline abstract_t">Reid DW, Walters EH, Johns DP, et al. Bronchial hyperresponsiveness and the bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2005; 24:489.</a></li><li><a class="nounderline abstract_t">Stanbrook MB, Kesten S. Bronchial hyperreactivity after lung transplantation predicts early bronchiolitis obliterans. Am J Respir Crit Care Med 1999; 160:2034.</a></li><li><a class="nounderline abstract_t">Worthy SA, Park CS, Kim JS, Müller NL. Bronchiolitis obliterans after lung transplantation: high-resolution CT findings in 15 patients. AJR Am J Roentgenol 1997; 169:673.</a></li><li><a class="nounderline abstract_t">Leung AN, Fisher K, Valentine V, et al. Bronchiolitis obliterans after lung transplantation: detection using expiratory HRCT. Chest 1998; 113:365.</a></li><li><a class="nounderline abstract_t">Vos R, Vanaudenaerde BM, Verleden SE, et al. Bronchoalveolar lavage neutrophilia in acute lung allograft rejection and lymphocytic bronchiolitis. J Heart Lung Transplant 2010; 29:1259.</a></li><li><a class="nounderline abstract_t">Chamberlain D, Maurer J, Chaparro C, Idolor L. Evaluation of transbronchial lung biopsy specimens in the diagnosis of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant 1994; 13:963.</a></li><li><a class="nounderline abstract_t">Sundaresan S, Trulock EP, Mohanakumar T, et al. Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group. Ann Thorac Surg 1995; 60:1341.</a></li><li><a class="nounderline abstract_t">Kramer MR, Stoehr C, Whang JL, et al. The diagnosis of obliterative bronchiolitis after heart-lung and lung transplantation: low yield of transbronchial lung biopsy. J Heart Lung Transplant 1993; 12:675.</a></li><li><a class="nounderline abstract_t">Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26:1229.</a></li><li><a class="nounderline abstract_t">Verleden SE, Von der Thüsen J, Roux A, et al. When tissue is the issue: A histological review of chronic lung allograft dysfunction. Am J Transplant 2020; 20:2644.</a></li><li><a class="nounderline abstract_t">Yousem SA, Duncan SR, Griffith BP. Interstitial and airspace granulation tissue reactions in lung transplant recipients. Am J Surg Pathol 1992; 16:877.</a></li><li><a class="nounderline abstract_t">Sato M, Waddell TK, Wagnetz U, et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011; 30:735.</a></li><li><a class="nounderline abstract_t">Ofek E, Sato M, Saito T, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. Mod Pathol 2013; 26:350.</a></li><li><a class="nounderline abstract_t">Verleden GM, Raghu G, Meyer KC, et al. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant 2014; 33:127.</a></li><li><a class="nounderline abstract_t">Sato M, Hwang DM, Waddell TK, et al. Progression pattern of restrictive allograft syndrome after lung transplantation. J Heart Lung Transplant 2013; 32:23.</a></li><li><a class="nounderline abstract_t">Verleden SE, Ruttens D, Vandermeulen E, et al. Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ? Transplantation 2013; 95:1167.</a></li><li><a class="nounderline abstract_t">Pakhale SS, Hadjiliadis D, Howell DN, et al. Upper lobe fibrosis: a novel manifestation of chronic allograft dysfunction in lung transplantation. J Heart Lung Transplant 2005; 24:1260.</a></li><li><a class="nounderline abstract_t">Verleden SE, de Jong PA, Ruttens D, et al. Functional and computed tomographic evolution and survival of restrictive allograft syndrome after lung transplantation. J Heart Lung Transplant 2014; 33:270.</a></li><li><a class="nounderline abstract_t">Iacono AT, Corcoran TE, Griffith BP, et al. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J 2004; 23:384.</a></li><li><a class="nounderline abstract_t">O'Hagan AR, Stillwell PC, Arroliga A, Koo A. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest 1999; 115:1459.</a></li><li><a class="nounderline abstract_t">Morrell MR, Despotis GJ, Lublin DM, et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010; 29:424.</a></li><li><a class="nounderline abstract_t">Benden C, Speich R, Hofbauer GF, et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation 2008; 86:1625.</a></li><li><a class="nounderline abstract_t">Verleden GM, Lievens Y, Dupont LJ, et al. Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation. Transplant Proc 2009; 41:1816.</a></li><li><a class="nounderline abstract_t">Fisher AJ, Rutherford RM, Bozzino J, et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2005; 5:537.</a></li><li><a class="nounderline abstract_t">Corcoran TE, Smaldone GC, Dauber JH, et al. Preservation of post-transplant lung function with aerosol cyclosporin. Eur Respir J 2004; 23:378.</a></li><li><a class="nounderline abstract_t">Benden C, Haughton M, Leonard S, Huber LC. Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review. J Heart Lung Transplant 2017; 36:921.</a></li><li><a class="nounderline abstract_t">Kapnadak SG, Morrell ED, Wai TH, et al. Variability in azithromycin practices among lung transplant providers in the International Society for Heart and Lung Transplantation Community. J Heart Lung Transplant 2022; 41:20.</a></li><li><a class="nounderline abstract_t">Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011; 37:164.</a></li><li><a class="nounderline abstract_t">Yates B, Murphy DM, Forrest IA, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005; 172:772.</a></li><li><a class="nounderline abstract_t">Gerhardt SG, McDyer JF, Girgis RE, et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003; 168:121.</a></li><li><a class="nounderline abstract_t">Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 77:1465.</a></li><li><a class="nounderline abstract_t">Gottlieb J, Szangolies J, Koehnlein T, et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85:36.</a></li><li><a class="nounderline abstract_t">Jain R, Hachem RR, Morrell MR, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010; 29:531.</a></li><li><a class="nounderline abstract_t">Vos R, Vanaudenaerde BM, Verleden SE, et al. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. Transplantation 2012; 94:101.</a></li><li><a class="nounderline abstract_t">Shitrit D, Bendayan D, Gidon S, et al. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 2005; 24:1440.</a></li><li><a class="nounderline abstract_t">Corris PA, Ryan VA, Small T, et al. A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax 2015; 70:442.</a></li><li><a class="nounderline abstract_t">Vos R, Vanaudenaerde BM, Ottevaere A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant 2010; 29:1358.</a></li><li><a class="nounderline abstract_t">Federica M, Nadia S, Monica M, et al. Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection. Clin Transplant 2011; 25:E381.</a></li><li><a class="nounderline abstract_t">Benden C, Boehler A. Long-term clarithromycin therapy in the management of lung transplant recipients. Transplantation 2009; 87:1538.</a></li><li><a class="nounderline abstract_t">Kesten S, Chaparro C, Scavuzzo M, Gutierrez C. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome. J Heart Lung Transplant 1997; 16:905.</a></li><li><a class="nounderline abstract_t">Belperio JA, Weigt SS, Fishbein MC, Lynch JP 3rd. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc 2009; 6:108.</a></li><li><a class="nounderline abstract_t">Hayes D Jr. A review of bronchiolitis obliterans syndrome and therapeutic strategies. J Cardiothorac Surg 2011; 6:92.</a></li><li><a class="nounderline abstract_t">Cairn J, Yek T, Banner NR, et al. Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003; 22:50.</a></li><li><a class="nounderline abstract_t">Whyte RI, Rossi SJ, Mulligan MS, et al. Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation. Ann Thorac Surg 1997; 64:945.</a></li><li><a class="nounderline abstract_t">Verleden GM, Dupont LJ, Van Raemdonck D, Vanhaecke J. Effect of switching from cyclosporine to tacrolimus on exhaled nitric oxide and pulmonary function in patients with chronic rejection after lung transplantation. J Heart Lung Transplant 2003; 22:908.</a></li><li><a class="nounderline abstract_t">Revell MP, Lewis ME, Llewellyn-Jones CG, et al. Conservation of small-airway function by tacrolimus/cyclosporine conversion in the management of bronchiolitis obliterans following lung transplantation. J Heart Lung Transplant 2000; 19:1219.</a></li><li><a class="nounderline abstract_t">Roman A, Bravo C, Monforte V, et al. Preliminary results of rescue therapy with tacrolimus and mycophenolate mofetil in lung transplanted patients with bronchiolitis obliterans. Transplant Proc 2002; 34:146.</a></li><li><a class="nounderline abstract_t">Verleden GM, Verleden SE, Vos R, et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study. Transpl Int 2011; 24:651.</a></li><li><a class="nounderline abstract_t">Ruttens D, Verleden SE, Demeyer H, et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial. PLoS One 2018; 13:e0193564.</a></li><li><a class="nounderline abstract_t">Hachem RR, Yusen RD, Chakinala MM, et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant 2007; 26:1012.</a></li><li><a class="nounderline abstract_t">Roman A, Ussetti P, Zurbano F, et al. A retrospective 12-month study of conversion to everolimus in lung transplant recipients. Transplant Proc 2011; 43:2693.</a></li><li><a class="nounderline abstract_t">Parada MT, Alba A, Sepúlveda C. Everolimus in lung transplantation in Chile. Transplant Proc 2010; 42:328.</a></li><li><a class="nounderline abstract_t">Strueber M, Warnecke G, Fuge J, et al. Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial. Am J Transplant 2016; 16:3171.</a></li><li><a class="nounderline abstract_t">Schwarz S, Jaksch P, Klepetko W, Hoetzenecker K. Immunosuppression after lung transplantation: the search for the holy grail continues. J Thorac Dis 2017; 9:1412.</a></li><li><a class="nounderline abstract_t">Jaksch P, Scheed A, Keplinger M, et al. A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2012; 31:950.</a></li><li><a class="nounderline abstract_t">Baskaran G, Tiriveedhi V, Ramachandran S, et al. Efficacy of extracorporeal photopheresis in clearance of antibodies to donor-specific and lung-specific antigens in lung transplant recipients. J Heart Lung Transplant 2014; 33:950.</a></li><li><a class="nounderline abstract_t">Del Fante C, Scudeller L, Oggionni T, et al. Long-Term Off-Line Extracorporeal Photochemotherapy in Patients with Chronic Lung Allograft Rejection Not Responsive to Conventional Treatment: A 10-Year Single-Centre Analysis. Respiration 2015; 90:118.</a></li><li><a class="nounderline abstract_t">Iacono A, Wijesinha M, Rajagopal K, et al. A randomised single-centre trial of inhaled liposomal cyclosporine for bronchiolitis obliterans syndrome post-lung transplantation. ERJ Open Res 2019; 5.</a></li><li><a class="nounderline abstract_t">Hayes D Jr, Zwischenberger JB, Mansour HM. Aerosolized tacrolimus: a case report in a lung transplant recipient. Transplant Proc 2010; 42:3876.</a></li><li><a class="nounderline abstract_t">Date H, Lynch JP, Sundaresan S, et al. The impact of cytolytic therapy on bronchiolitis obliterans syndrome. J Heart Lung Transplant 1998; 17:869.</a></li><li><a class="nounderline abstract_t">Whitford H, Walters EH, Levvey B, et al. Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial. Transplantation 2002; 73:1793.</a></li><li><a class="nounderline abstract_t">Reams BD, Musselwhite LW, Zaas DW, et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant 2007; 7:2802.</a></li><li><a class="nounderline abstract_t">Moniodis A, Townsend K, Rabin A, et al. Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction. J Heart Lung Transplant 2018; 37:340.</a></li><li><a class="nounderline abstract_t">Benden C, Goldfarb SB, Edwards LB, et al. The registry of the International Society for Heart and Lung Transplantation: seventeenth official pediatric lung and heart-lung transplantation report--2014; focus theme: retransplantation. J Heart Lung Transplant 2014; 33:1025.</a></li><li><a class="nounderline abstract_t">Verleden SE, Todd JL, Sato M, et al. Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study. Am J Transplant 2015; 15:2223.</a></li><li><a class="nounderline abstract_t">Biswas Roy S, Panchanathan R, Walia R, et al. Lung Retransplantation for Chronic Rejection: A Single-Center Experience. Ann Thorac Surg 2018; 105:221.</a></li><li><a class="nounderline abstract_t">Sommer W, Ius F, Kühn C, et al. Technique and Outcomes of Less Invasive Lung Retransplantation. Transplantation 2018; 102:530.</a></li><li><a class="nounderline abstract_t">Halloran K, Aversa M, Tinckam K, et al. Comprehensive outcomes after lung retransplantation: A single-center review. Clin Transplant 2018; 32:e13281.</a></li><li><a class="nounderline abstract_t">Brugière O, Thabut G, Castier Y, et al. Lung retransplantation for bronchiolitis obliterans syndrome: long-term follow-up in a series of 15 recipients. Chest 2003; 123:1832.</a></li><li><a class="nounderline abstract_t">Kawut SM, Lederer DJ, Keshavjee S, et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med 2008; 177:114.</a></li><li><a class="nounderline abstract_t">Levine SM, Bryan CL. Bronchiolitis obliterans in lung transplant recipients. The "thorn in the side" of lung transplantation. Chest 1995; 107:894.</a></li><li><a class="nounderline abstract_t">Finlen Copeland CA, Snyder LD, Zaas DW, et al. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med 2010; 182:784.</a></li><li><a class="nounderline abstract_t">Burton CM, Carlsen J, Mortensen J, et al. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2007; 26:681.</a></li><li><a class="nounderline abstract_t">Sato M, Ohmori-Matsuda K, Saito T, et al. Time-dependent changes in the risk of death in pure bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant 2013; 32:484.</a></li><li><a class="nounderline abstract_t">Riise GC, Andersson BA, Kjellström C, et al. Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant. Eur Respir J 1999; 14:1123.</a></li><li><a class="nounderline abstract_t">Reynaud-Gaubert M, Marin V, Thirion X, et al. Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of post-transplant airway obliteration. J Heart Lung Transplant 2002; 21:721.</a></li><li><a class="nounderline abstract_t">Meloni F, Vitulo P, Cascina A, et al. Bronchoalveolar lavage cytokine profile in a cohort of lung transplant recipients: a predictive role of interleukin-12 with respect to onset of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2004; 23:1053.</a></li><li><a class="nounderline abstract_t">Neurohr C, Huppmann P, Samweber B, et al. Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients. J Heart Lung Transplant 2009; 28:468.</a></li><li><a class="nounderline abstract_t">Vanaudenaerde BM, De Vleeschauwer SI, Vos R, et al. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2008; 8:1911.</a></li><li><a class="nounderline abstract_t">Bankier AA, Van Muylem A, Knoop C, et al. Bronchiolitis obliterans syndrome in heart-lung transplant recipients: diagnosis with expiratory CT. Radiology 2001; 218:533.</a></li><li><a class="nounderline abstract_t">Konen E, Gutierrez C, Chaparro C, et al. Bronchiolitis obliterans syndrome in lung transplant recipients: can thin-section CT findings predict disease before its clinical appearance? Radiology 2004; 231:467.</a></li><li><a class="nounderline abstract_t">Knollmann FD, Kapell S, Lehmkuhl H, et al. Dynamic high-resolution electron-beam CT scanning for the diagnosis of bronchiolitis obliterans syndrome after lung transplantation. Chest 2004; 126:447.</a></li><li><a class="nounderline abstract_t">Bankier AA, Mehrain S, Kienzl D, et al. Regional heterogeneity of air trapping at expiratory thin-section CT of patients with bronchiolitis: potential implications for dose reduction and CT protocol planning. Radiology 2008; 247:862.</a></li><li><a class="nounderline abstract_t">Brugière O, Thabut G, Mal H, et al. Exhaled NO may predict the decline in lung function in bronchiolitis obliterans syndrome. Eur Respir J 2005; 25:813.</a></li><li><a class="nounderline abstract_t">Gabbay E, Walters EH, Orsida B, et al. Post-lung transplant bronchiolitis obliterans syndrome (BOS) is characterized by increased exhaled nitric oxide levels and epithelial inducible nitric oxide synthase. Am J Respir Crit Care Med 2000; 162:2182.</a></li><li><a class="nounderline abstract_t">Golocheikine AS, Saini D, Ramachandran S, et al. Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation. Transpl Immunol 2008; 18:260.</a></li><li><a class="nounderline abstract_t">LaPar DJ, Burdick MD, Emaminia A, et al. Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker. Ann Thorac Surg 2011; 92:470.</a></li><li><a class="nounderline abstract_t">Agbor-Enoh S, Wang Y, Tunc I, et al. Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation. EBioMedicine 2019; 40:541.</a></li><li><a class="nounderline abstract_t">Agbor-Enoh S, Jackson AM, Tunc I, et al. Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis. J Heart Lung Transplant 2018; 37:925.</a></li><li><a class="nounderline abstract_t">Iasella CJ, Hoji A, Popescu I, et al. Type-1 immunity and endogenous immune regulators predominate in the airway transcriptome during chronic lung allograft dysfunction. Am J Transplant 2021; 21:2145.</a></li><li><a class="nounderline abstract_t">Li D, Duan Q, Weinkauf J, et al. Azithromycin prophylaxis after lung transplantation is associated with improved overall survival. J Heart Lung Transplant 2020; 39:1426.</a></li><li><a class="nounderline abstract_t">De Muynck B, Van Herck A, Sacreas A, et al. Successful Pseudomonas aeruginosa eradication improves outcomes after lung transplantation: a retrospective cohort analysis. Eur Respir J 2020; 56.</a></li></ol></div><div id="topicVersionRevision">Topic 4654 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30962148" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31548030" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31027539" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31958356" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Identification and characterization of chronic lung allograft dysfunction patients with mixed phenotype: A single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32418864" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35351385" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Phenotyping CLAD after single lung transplant: Limits and prognostic assessment of the 2019 ISHLT classification system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32917480" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Longitudinal lung function measurements in single lung transplant recipients with chronic lung allograft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32917480" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Longitudinal lung function measurements in single lung transplant recipients with chronic lung allograft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7705164" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796156" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15136293" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11897517" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16102441" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Transcript signatures of lymphocytic bronchitis in lung allograft biopsy specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9456123" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pulmonary retransplantation: predictors of graft function and survival in 230 patients. Pulmonary Retransplant Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919620" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Primary graft dysfunction and long-term pulmonary function after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26186804" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3928482" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pathologic pulmonary alterations in long-term human heart-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12016109" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Oligoclonal CD4(+) T cell expansions in lung transplant recipients with obliterative bronchiolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232557" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21414808" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7684535" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Are multiple immunopathogenetic events occurring during the development of obliterative bronchiolitis and acute rejection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232567" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25443870" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26967790" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29146602" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37054889" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Specific human leucocyte antigen-DQ risk epitope mismatches are associated with chronic lung allograft dysfunction after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9270635" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521198" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9806388" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11179119" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Influence of donor and recipient HLA locus mismatching on development of obliterative bronchiolitis after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7664853" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Post-transplant obstructive lung disease ("bronchiolitis obliterans"): a clinical comparative study of bone marrow and lung transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9824023" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bronchiolitis obliterans after lung transplantation: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7609567" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19716040" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10051258" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Analysis of risk factors for the development of bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18263803" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16340783" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The significance of a single episode of minimal acute rejection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1847251" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15297275" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167845" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34183227" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association between chronic lung allograft dysfunction and human Cytomegalovirus UL40 peptide variants in lung-transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467538" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Graft Loss and CLAD-Onset Is Hastened by Viral Pneumonia After Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996256" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303014" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19295317" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19303808" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Detection of Epstein-Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35843852" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The effect of COVID-19 on transplant function and development of CLAD in lung transplant patients: A multicenter experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36925381" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Invasive fungal infections after respiratory viral infections in lung transplant recipients are associated with lung allograft failure and chronic lung allograft dysfunction within 1 year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19459819" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117741" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337673" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23328531" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Interaction between Pseudomonas and CXC chemokines increases risk of bronchiolitis obliterans syndrome and death in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11996238" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17158279" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399944" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Role of nitric oxide in experimental obliterative bronchiolitis (chronic rejection) in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7871557" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Both alloantigen-dependent and -independent factors influence chronic allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9256186" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Immunohistochemical localization of nitric oxide synthase and the oxidant peroxynitrite in lung transplant recipients with obliterative bronchiolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18573422" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Immunological link between primary graft dysfunction and chronic lung allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12658195" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19716037" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Gastroesophageal reflux in bronchiolitis obliterans syndrome: a new perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20418369" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Reflux-induced collagen type v sensitization: potential mediator of bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21276737" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Heterogeneity of chronic lung allograft dysfunction: insights from protein expression in broncho alveolar lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21801907" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25359357" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26290637" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pre-lung transplant measures of reflux on impedance are superior to pH testing alone in predicting early allograft injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36609090" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Laparoscopic fundoplication after lung transplantation does not appear to alter lung function trajectory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16433773" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Impact of lung transplant operation on bronchiolitis obliterans syndrome in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23721028" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pre-transplant presence of antibodies to MICA and HLA class I or II are associated with an earlier onset of bronchiolitis obliterans syndrome in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14680094" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Post-transplant bronchiolitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15797754" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Bronchial hyperresponsiveness and the bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588625" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Bronchial hyperreactivity after lung transplantation predicts early bronchiolitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9275875" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Bronchiolitis obliterans after lung transplantation: high-resolution CT findings in 15 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498953" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Bronchiolitis obliterans after lung transplantation: detection using expiratory HRCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20673640" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Bronchoalveolar lavage neutrophilia in acute lung allograft rejection and lymphocytic bronchiolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7865530" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Evaluation of transbronchial lung biopsy specimens in the diagnosis of bronchiolitis obliterans after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8526624" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8369329" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The diagnosis of obliterative bronchiolitis after heart-lung and lung transplantation: low yield of transbronchial lung biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18096473" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32185874" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : When tissue is the issue: A histological review of chronic lung allograft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1415906" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Interstitial and airspace granulation tissue reactions in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21419659" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23018877" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24374027" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A new classification system for chronic lung allograft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23260703" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Progression pattern of restrictive allograft syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23425818" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143243" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Upper lobe fibrosis: a novel manifestation of chronic allograft dysfunction in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24461432" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Functional and computed tomographic evolution and survival of restrictive allograft syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15065826" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334173" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19853479" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19077900" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19545735" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15707408" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15065825" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Preservation of post-transplant lung function with aerosol cyclosporin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28662986" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34785136" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Variability in azithromycin practices among lung transplant providers in the International Society for Heart and Lung Transplantation Community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20562124" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15976371" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12672648" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15167610" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18192909" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20133163" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22461039" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143268" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25714615" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20619683" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21418327" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19461491" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Long-term clarithromycin therapy in the management of lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9322139" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131536" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Chronic lung allograft rejection: mechanisms and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21767391" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : A review of bronchiolitis obliterans syndrome and therapeutic strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12531413" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9354506" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12909472" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Effect of switching from cyclosporine to tacrolimus on exhaled nitric oxide and pulmonary function in patients with chronic rejection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11124493" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Conservation of small-airway function by tacrolimus/cyclosporine conversion in the management of bronchiolitis obliterans following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11959227" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Preliminary results of rescue therapy with tacrolimus and mycophenolate mofetil in lung transplanted patients with bronchiolitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21401732" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29624575" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919621" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911148" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : A retrospective 12-month study of conversion to everolimus in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20172343" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Everolimus in lung transplantation in Chile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27104933" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28740645" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Immunosuppression after lung transplantation: the search for the holy grail continues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22884382" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24906794" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Efficacy of extracorporeal photopheresis in clearance of antibodies to donor-specific and lung-specific antigens in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26112178" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Long-Term Off-Line Extracorporeal Photochemotherapy in Patients with Chronic Lung Allograft Rejection Not Responsive to Conventional Treatment: A 10-Year Single-Centre Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31687370" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : A randomised single-centre trial of inhaled liposomal cyclosporine for bronchiolitis obliterans syndrome post-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21094875" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Aerosolized tacrolimus: a case report in a lung transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9773858" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : The impact of cytolytic therapy on bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12085003" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17924993" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28431983" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25242126" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : The registry of the International Society for Heart and Lung Transplantation: seventeenth official pediatric lung and heart-lung transplantation report--2014; focus theme: retransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25940517" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29100649" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Lung Retransplantation for Chronic Rejection: A Single-Center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28787308" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Technique and Outcomes of Less Invasive Lung Retransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29754418" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Comprehensive outcomes after lung retransplantation: A single-center review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796157" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Lung retransplantation for bronchiolitis obliterans syndrome: long-term follow-up in a series of 15 recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901410" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Outcomes after lung retransplantation in the modern era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7705149" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Bronchiolitis obliterans in lung transplant recipients. The "thorn in the side" of lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20508211" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17613397" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433813" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Time-dependent changes in the risk of death in pure bronchiolitis obliterans syndrome (BOS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10596701" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100898" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of post-transplant airway obliteration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15454171" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Bronchoalveolar lavage cytokine profile in a cohort of lung transplant recipients: a predictive role of interleukin-12 with respect to onset of bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19416775" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18786233" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11161175" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Bronchiolitis obliterans syndrome in heart-lung transplant recipients: diagnosis with expiratory CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15128992" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Bronchiolitis obliterans syndrome in lung transplant recipients: can thin-section CT findings predict disease before its clinical appearance?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302730" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Dynamic high-resolution electron-beam CT scanning for the diagnosis of bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18375838" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Regional heterogeneity of air trapping at expiratory thin-section CT of patients with bronchiolitis: potential implications for dose reduction and CT protocol planning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863637" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Exhaled NO may predict the decline in lung function in bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11112135" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Post-lung transplant bronchiolitis obliterans syndrome (BOS) is characterized by increased exhaled nitric oxide levels and epithelial inducible nitric oxide synthase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18047935" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21801908" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30692045" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29500138" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33078555" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Type-1 immunity and endogenous immune regulators predominate in the airway transcriptome during chronic lung allograft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33041181" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Azithromycin prophylaxis after lung transplantation is associated with improved overall survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32471935" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Successful Pseudomonas aeruginosa eradication improves outcomes after lung transplantation: a retrospective cohort analysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
